checkAd
    Startseite > Aktien > Virios Therapeutics > Nachrichten
    Virios Therapeutics Aktie
    0,2184
     
    USD
    +4,00 %
    +0,0084 USD
    Letzter Kurs 02:00:00 NYSE
    0,2183
     
    USD
    100 STK
    Geldkurs 31.05.24
    0,2317
     
    USD
    100 STK
    Briefkurs 31.05.24
    ISIN: US92829J1043 · WKN: A2QD9X · SYM: VIRI · USA

    Neueste Nachrichten

    Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
    22.05.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
    20.05.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
    17.05.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
    09.05.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
    02.05.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
    26.03.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
    29.02.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
    28.02.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
    22.01.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
    02.01.24 · globenewswire · Virios Therapeutics
    Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
    13.11.23 · globenewswire · Virios Therapeutics
    Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
    06.11.23 · globenewswire · Virios Therapeutics